Update (June 30, 2026): CPMA (Trutect) Pivotal Trial — 100% Survival in Experimental Canine Parvovirus Challenge

Bottom line.

• Larson et al. (2024, JAVMA) report the pivotal USDA licensure study for canine parvovirus monoclonal antibody (CPMA, now marketed as Trutect): a randomized, blinded, placebo-controlled experimental CPV-2b challenge in 28 Beagle puppies.
• A single IV dose of CPMA (0.2 mL/kg) given on Day 4 after confirmed fecal shedding prevented mortality in 100% of treated dogs (21/21) versus 57% mortality in placebo-treated controls (P = .0017).
• CPMA-treated dogs also had significantly less severe fever, vomiting, diarrhea, fecal viral shedding, and lymphopenia than controls, without impairing the dogs' own antibody (IgM) response.
• The USDA granted CPMA full approval in December 2025 (rebranded Trutect), having issued a conditional license in 2023; this is the first and only USDA-licensed targeted treatment for CPV-2.
• This is a clinician-facing evidence summary - confirm current product labeling and dosing before prescribing.

Study facts

• Product: Canine Parvovirus Monoclonal Antibody (CPMA), now marketed as Trutect (Elanco Animal Health).
• Mechanism: Chimeric monoclonal antibody that binds and neutralizes CPV-2, providing passive immunity/targeted antiviral activity during active infection.
• Treatment dose (per pivotal study): 0.2 mL/kg, single IV dose, administered once fecal CPV-2 shedding is confirmed.
• Regulatory status: USDA conditional license 2023; full USDA approval December 2025.^1,2
• Indication per pivotal study: Adjunct to standard supportive care in dogs with confirmed CPV-2 infection - not a replacement for fluids, antiemetics, and antimicrobial therapy.

Treating a confirmed parvo case today?

Get an instant cited answer for the patient in front of you - no signup needed for your first question.

Try Voyage Clinical Desk

What the evidence shows

Study design

This pivotal, IACUC-approved study was conducted to support USDA product licensure. Twenty-eight healthy, 8-week-old, CPV-2-seronegative purpose-bred Beagle puppies were randomized by litter to a control group (n=7, saline) or CPMA-treatment group (n=21). All dogs were challenged intranasally with 10^4.2 TCID50 of virulent CPV-2b on Day 0. By Day 4, all 28 dogs were shedding virus and showing early clinical signs (86% had fevers, 61% abnormal feces, 79% lethargy, 96% inappetence), with no significant difference in severity between groups prior to treatment. Each dog then received a single IV dose of CPMA (0.2 mL/kg) or an equal volume of saline by masked study personnel. No further treatment was administered to either group, per USDA pivotal-trial requirements, and dogs were observed through Day 14.¹

Results

All 21 CPMA-treated dogs survived. In the control group, clinical signs progressed to humane endpoint and death in 4 of 7 dogs (57%) on Day 7 or 8. The prevented fraction for mortality was 1.00 (95% CI, 0.73-1.00; Fisher exact test, P = .0017). Beyond mortality prevention, CPMA-treated dogs had significantly reduced fever by Day 5 (P < .0001) and significantly less fecal viral shedding by Day 6 (P < .0001) and Day 7 (P = .0122) compared to controls. Treatment with CPMA produced high anti-CPV-2 hemagglutination-inhibition titers by Day 5 (median 2,560), while controls remained seronegative. Importantly, both groups showed similar endogenous IgM responses, indicating CPMA treatment does not blunt the dog's own adaptive immune response to natural infection.¹

Regulatory trajectory and real-world rollout

Following the 2023 conditional USDA license, Elanco compiled real-world post-launch data showing 93% survival among CPMA-treated puppies and an average 1.87-day reduction in hospital length of stay. The USDA granted full approval in December 2025, with the product rebranded Trutect; the agency separately extended the indication to passive immunity/prophylaxis in exposed but uninfected puppies in June 2025.² This represents the only USDA-licensed antiviral specifically targeting CPV-2, distinct from broad-spectrum supportive measures.

How this fits clinical practice

The pivotal challenge study is a methodologically strong dataset for an emerging therapy: randomized, blinded, placebo-controlled, with mortality as the primary endpoint and a clean statistical result. The key clinical takeaway is timing - CPMA was administered after confirmed shedding (Day 4 post-challenge, correlating with early clinical signs), and the prevented-fraction estimate applies to that window. Practices should not interpret this data as supporting indefinite delay in supportive care initiation; CPMA is additive to, not a substitute for, fluids, antiemetics, and antimicrobial coverage. Given the cost of CPMA relative to a single bottle of crystalloids, the strongest economic and clinical case is in patients where reduced length of stay (consistent with the morbidity reductions seen in this study) offsets acquisition cost - a question addressed further by real-world shelter outcomes data.

Always confirm current Trutect/CPMA product labeling, dosing, and indications against the manufacturer and current formulary before use.

References

1. Larson L, Miller L, Margiasso M, et al. 2024. Early Administration of Canine Parvovirus Monoclonal Antibody Prevented Mortality after Experimental Challenge. J Am Vet Med Assoc 262(4):506-512. https://avmajournals.avma.org/view/journals/javma/262/4/javma.23.09.0541.xml
2. dvm360. 2025. USDA grants full approval for novel canine parvovirus therapy. December 16, 2025. https://www.dvm360.com/view/usda-grants-full-approval-for-novel-canine-parvovirus-therapy

Changelog

• 2026-06-30: First published.